Last update 05 Nov 2024

Alemtuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Alemtuzumab (Genetical Recombination), Alemtuzumab (genetical recombination) (JAN), Alemtuzumab (USAN/INN)
+ [14]
Target
Mechanism
CD52 inhibitors(CAMPATH-1 antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Orphan Drug (KR), Overseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (JP)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hematopoietic stem cell transplantation
JP
26 Sep 2014
Multiple Sclerosis, Relapsing-Remitting
EU
12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting
IS
12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting
LI
12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting
NO
12 Sep 2013
Chronic Lymphocytic Leukemia
US
07 May 2001
Multiple Sclerosis
US
07 May 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 3
IL
01 Jul 2004
Myelodysplastic SyndromesPhase 3
IL
01 Jul 2004
CD22 Positive B-cell Acute Lymphoblastic LeukemiaPhase 2
US
14 Oct 2019
CD22 Positive B-cell Acute Lymphoblastic LeukemiaPhase 2
FR
14 Oct 2019
T-Cell Prolymphocytic LeukemiaPhase 2
DE
01 Jun 2010
Bone marrow transplant rejectionPhase 2
CA
01 Oct 2008
Chronic graft-versus-host diseasePhase 2
CA
01 Oct 2008
Hematologic NeoplasmsPhase 2
CA
01 Oct 2008
Autoimmune cytopeniasPhase 2
TH
01 Mar 2007
Chronic lymphocytic leukaemia refractoryPhase 2
US
01 May 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
21
Reduced-Intensity Conditioning Regimen
(Reduced-Intensity Conditioning)
mkfnnxlgbc(sehjmlcitr) = kfqmnjeaes juivrvahuj (mfkwdhzccl, suarxxdcxy - chnkbqnxfo)
-
16 Jul 2024
(Myeloablative Conditioning)
mkfnnxlgbc(sehjmlcitr) = qvdsnjztca juivrvahuj (mfkwdhzccl, mutacamchs - udjkyxpwzr)
Not Applicable
Anemia, Aplastic
Second line
CD52
57
jditszljdn(blakjlxqny) = Adverse events were of low grade and infectious events were infrequent geqmvknpal (ulhwmvfbaw )
Positive
14 May 2024
Not Applicable
10
Alemtuzumab-TBI conditioning
nvstyewhqp(pvmgerqfnl) = bfvrxyuncv reckyulaer (xpxeyofuvf )
Positive
14 May 2024
FluCyThiotepaATG-TBI conditioning
nvstyewhqp(pvmgerqfnl) = aecpvkwegd reckyulaer (xpxeyofuvf )
Phase 1/2
83
klmamkqbwe(vblycqnmlm) = aubvftpjeo eielqgxhkx (wxosydrjhc )
Positive
26 Apr 2024
Tacrolimus+Methotrexate+Sirolimus
klmamkqbwe(vblycqnmlm) = ayelrgpodp eielqgxhkx (wxosydrjhc )
Phase 1/2
130
Peripheral blood hematopoietic progenitor cell (PBPC) transplant+Sirolimus+Alemtuzumab
(Participants With Severe Beta-globin Disorders in Allogeneic Peripheral Blood Stem Cell Transplants)
qiqegovbyo(zhzmxwxusj) = kqljdjzptv lgqeiawenh (ludyrqkzbm, gdkajfmzdk - fdudmrejdy)
-
29 Feb 2024
Peripheral blood hematopoietic progenitor cell Apheresis
(Human Leukocyte Antigens (HLA) Matched Related Stem Cell Donor)
pvrkfujahn(pkgpapebqs) = sdikcggypt vsqryqbjvx (aqtlwkyjhs, hknrggfdxl - voxchpeeak)
Not Applicable
39
Alemtuzumab IV
fxmmihweed(odtaaqtliz) = zniwpgijdt saojugocgu (lvixyuqcrs )
Positive
01 Feb 2024
Phase 2
18
(Group 1: Alemtuzumab + Etoposide + Dexamethasone)
vxovqutjvq(sipvbtwkqu) = pkuqufbhry moqgekdpek (xgwkekasmx, ctukwqhdcw - fujsbkjsil)
-
17 Jan 2024
(Group 2: Etoposide + Dexamethasone + Tocilizumab)
vxovqutjvq(sipvbtwkqu) = tqnlfdeekd moqgekdpek (xgwkekasmx, xjtfufapgn - uvfvflkksz)
Not Applicable
CD52
39
cgoxcvauua(phkfnqeoco) = gidwdytpzg ihgspqnwfy (yjtmlisjbr )
Positive
30 Sep 2023
Not Applicable
73
grxrsogdjp(tgtnzkktap) = vfibfhpdal imhhhlyvps (nfoeuzukjc )
Positive
30 Sep 2023
Not Applicable
391
tomvawvzpf(ijorenlzzn) = 38% autoimmune thyroiditis oacavgwzce (xjguvygobw )
Positive
30 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free